LFF-571
Also known as: GE2270A semisynthetic derivative, LFF571
Source LFF-571 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
LFF-571 is a semisynthetic thiopeptide antibiotic derived from GE2270A, developed by Novartis. It demonstrates potent in vitro activity against Clostridioides difficile and other gram-positive pathogens. A Phase II clinical trial evaluated LFF-571 versus vancomycin for moderate Clostridioides difficile infection, showing comparable efficacy but not superior outcomes. Development has not progressed to Phase III as of available data.
Mechanism of Action
Inhibits bacterial protein synthesis by binding to elongation factor Tu (EF-Tu) in complex with GTP, preventing aminoacyl-tRNA delivery to the ribosomal A site, thereby halting translation in susceptible gram-positive bacteria.
Routes of Administration
Goals & Uses
- Gram-positive bacterial infection treatmentAntimicrobialLow
- Reduction of CDI recurrenceAntimicrobial / GastrointestinalLow
- Treatment of Clostridioides difficile infectionAntimicrobialModerate
Contraindications
- Hypersensitivity to thiopeptide antibiotics or GE2270A derivativesAllergyHigh
Adverse Effects
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Abdominal painGastrointestinalUncommonPain or discomfort in the abdomen
Drug Interactions
- CYP3A4 substratesLow
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorization granted; limited EU trial data publicly available.
- United StatesInvestigationalInvestigated under IND for CDI; Phase II completed (NCT01232595); no NDA filed as of available data.
Not approved by any regulatory authority. Evaluated in Phase II clinical trials (NCT01232595) for Clostridioides difficile infection. Novartis has not advanced the compound to Phase III registration trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is LFF-571?
LFF-571 is a semisynthetic thiopeptide antibiotic derived from GE2270A, developed by Novartis. It demonstrates potent in vitro activity against Clostridioides difficile and other gram-positive pathogens. A Phase II clinical trial evaluated LFF-571 versus vancomycin for moderate Clostridioides difficile infection, showing comparable efficacy but not superior outcomes. Development has not progressed to Phase III as of available data.
What is LFF-571 used for?
LFF-571 is educationally associated with: Gram-positive bacterial infection treatment, Reduction of CDI recurrence, Treatment of Clostridioides difficile infection. Educational only — not medical advice.
How is LFF-571 administered?
Recorded routes of administration: Oral.
What are the potential side effects of LFF-571?
Reported adverse effects include: Headache, Nausea, Vomiting, Elevated liver enzymes, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid LFF-571?
Recorded contraindications: Hypersensitivity to thiopeptide antibiotics or GE2270A derivatives. Consult a qualified clinician before use.